Evolving Treatment Options for Thrombocytopenic Patients With MDS

Download these slides from an expert video on strategies for treating patients with myelodysplastic syndrome and thrombocytopenia.
Rami S. Komrokji, MD
Format: Microsoft PowerPoint (.ppt)
File Size: 277 KB
Released: January 21, 2021

Acknowledgements

Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by an educational grant from
Bristol-Myers Squibb

Related Content

Drs. Amy DeZern and Srdan Verstovsek discuss their top abstract choices from ASH 2020 in MDS and MPNs, from Clinical Care Options (CCO)

Amy E. DeZern, MD, MHS Srdan Verstovsek, MD, PhD Released: February 23, 2021

From Clinical Care Options, experts review key data in MDS and MPNs from ASH 2020

Amy E. DeZern, MD, MHS Srdan Verstovsek, MD, PhD Physicians: maximum of 1.0 AMA PRA Category 1 Credit Released: February 16, 2021 Expired: February 15, 2022

Brief expert video from Clinical Care Options (CCO) on recommended treatment strategies for patients with myelodysplastic syndrome (MDS) and thrombocytopenia

Rami S. Komrokji, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: January 21, 2021 Expired: January 20, 2022

Brief expert video from Clinical Care Options (CCO) on recommended treatment strategies for anemia in patients with myelodysplastic syndrome (MDS)

Rami S. Komrokji, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: January 19, 2021 Expired: January 18, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue